Gorgi Kozeski, DO
Clinical Cardiac Electrophysiology · Altoona, PANPI 1689817272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,356 of the $134,154 with a category attached, or 71.8%. 30 manufacturers reported payments, led by Johnson & Johnson at 50.4% of the total. Reporting peaked in 2019 at $57,921 and has fallen 72.1% since, to $16,180 in 2025.
Across 861 payments — averaging $155.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$68K
- E.r. Squibb & Sons, L.L.C.$26K
- Boston Scientific$10K
- Pfizer$10K
- Abbott$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
- plus $10K from 24 others
What the payments were for
- Consulting fees$4,3063%
- Speaking & faculty fees$96,35672%
- Travel & lodging$9,0797%
- Food & beverage$24,30718%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 128 | $67,564 |
| E.r. Squibb & Sons, L.L.C. | 65 | $26,044 |
| Boston Scientific | 250 | $10,072 |
| Pfizer | 117 | $9,896 |
| Abbott | 89 | $5,611 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $4,613 |
| Medtronic(2 entities) | 54 | $3,571 |
| Biosense Webster, Inc. | 57 | $2,230 |
| Novartis | 19 | $1,964 |
| Biotronik Inc. | 11 | $1,607 |
| AstraZeneca | 5 | $215 |
| Bridgebio Pharma, Inc. | 1 | $106 |
| Impulse Dynamics (USA) Inc. | 2 | $95 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $82 |
| Abiomed | 2 | $66 |
| Inari Medical, Inc. | 2 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Cardiofocus, Inc. | 2 | $49 |
| Angiodynamics, Inc. | 1 | $46 |
| Celonova Biosciences, Inc. | 1 | $37 |
| Atricure, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Merck | 1 | $16 |
| Cordis US CORP. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$66,287
- CAMZYOS$17,957
- ELIQUIS$14,450
- LifeVest$4,000
- SelectSecure$2,338
- ENTRESTO$1,706
- Watchman$1,281
- AVEIR$908
- Accent Pacemaker$800
- Agilis HisPro$263
- Arctic Front$225
- Quadra Allure MP RF CRT Pacemkr$146
- QUADRA ASSURA$132
- Confirm Rx$117
- SelectSite$116
- Allure Quadra RF CRT Pacemaker$112
- GALLANT$112
- UNIFY ASSURA$109
- INTELLAMAP ORION$108
- Carto 3$107
How this compares
$134,154 in reported general payments places this provider in the 85th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 904 | $790,903 |
| EntrestoSacubitril/Valsartan | 332 | $309,423 |
| XareltoRivaroxaban | 282 | $237,196 |
| FarxigaDapagliflozin Propanediol | 147 | $132,906 |
| MultaqDronedarone Hcl | 79 | $82,842 |
| JardianceEmpagliflozin | 78 | $77,010 |
| Metoprolol Succinate | 870 | $16,557 |
| Repatha SureclickEvolocumab | 14 | $13,326 |
| Flecainide Acetate | 124 | $4,999 |
| Valsartan | 185 | $4,736 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $3,739 |
| Propafenone Hcl ErPropafenone Hcl | 17 | $3,555 |
| Rosuvastatin Calcium | 148 | $3,087 |
| Atorvastatin Calcium | 189 | $2,561 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 93 | $2,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,896 | $790,903904 claims |
| NovartisEntresto | $1,964 | $309,423332 claims |
| Johnson & JohnsonXarelto | $67,564 | $237,196282 claims |
| AstraZenecaFarxiga | $215 | $132,906147 claims |
| Sanofi-aventis U.S. LLCMultaq | $52 | $82,84279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Altoona
- Seth WorleyLancaster$3.7M
- John ChenaridesPittsburgh$750K
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pugazhendhi VijayaramanWilkes Barre$594K
- Pasquale SantangeliPhiladelphia$581K
- Joshua SilversteinPittsburgh$557K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
- Timothy MarkmanPhiladelphia$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.